Carnitine abnormalities in patients with renal insufficiency. Pathophysiological and therapeutical aspects.
Carnitine abnormalities in patients with renal insufficiency. Pathophysiological and therapeutical aspects.
复制标题
肾功能不全患者的肉碱异常。
作者:
Christoph Wanner;W. H. Hörl
L-Carnitine therapy has become of interest for neph rologists, since Böhmer et al.[I] reported that patients with end-stage renal failure on chronic hemodialysis (HD) treatment display disturbed carnitine metabolism and carnitine deficiency. During recent years many re searchers have tried to demonstrate that exogenous ad ministration of L-carnitine improves uremia-induced subpathologies. However, inconsistent results about the benefits of L-carnitine supplementation have been re ported in patients suffering from this secondary form of carnitine deficiency. Advances in methodology gave new insights into the mechanism of carnitine metabolism in chronically uremic states. This review highlights the cur rent knowledge of carnitine metabolism in various forms of renal insufficiency and focuses particularly on the role of L-carnitine therapy. sine than females [9]. If, however, the structural and metabolic integrity of the kidneys is destroyed by chronic renal failure, a disturbance of the biosynthesis of carni tine or altered regulation of the organ distribution of the precursors could be possible. Deficiency of plasma 6-N-trimethyllysine as a potential cause of carnitine defi ciency in uremia could be ruled out. HD patients exhibit about fourfold higher predialysis concentrations of trimethyllysine than normal persons. Trimethyllysine is removed in great quantities during HD, but postdialysis values are still above normal [10],